AstraZeneca has recently launched a new global health tech business, Evinova, with the goal of revolutionizing the clinical trial process. The company aims to reduce the time and cost of clinical trials while making the process more accessible for patients.
Evinova will provide global services to CROs and pharmaceutical companies, helping them design, run, and monitor clinical trials. The company will charge customers for access to its technology and operate on a revenue-based model.
By creating Evinova, AstraZeneca hopes to address the challenges and inefficiencies in the clinical trial process, ultimately making it easier for patients to participate and improving the overall effectiveness of the trials. This new business venture reflects AstraZeneca’s commitment to advancing healthcare and utilizing technology to improve the drug development process.